Aryx Therapeutics (ARYX) 0.0151 $ARYX SarlaFlex Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aryx Therapeutics (ARYX) 0.0151 $ARYX

SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.

Biomarker Partnering Terms and Agreements: 2013 Report is Out Now for Review
M2 - Mon Nov 25, 10:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/fn742d/biomarker) has announced the addition of the "Biomarker Partnering Terms and Agreements" report to their offering. This report contains over 800 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007. The chapter is organized by specific diagnpstics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , stage of development, deal type, therapy area, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned: - ARYx Therapeutics - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Cardiome Pharma - Daiichi Sankyo - Dynavax Technologies - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - GTx - Hyperion Therapeutics - Inspire Pharmaceuticals - Janssen Research & Development - KaloBios Pharmaceuticals - La Jolla Pharmaceutical - Merck and Co - Novartis Consumer Health - Novo Nordisk - OncoGenex Pharmaceuticals - Pfizer - PhotoMedex - Procter & Gamble - Sigma-Tau - Solvay - Transcept Pharmaceuticals - Ucyclyd Pharma - Valeant Pharmaceuticals - Wyeth - Xenoport - Zogenix For more information visit http://www.researchandmarkets.com/research/fn742d/biomarker About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics - 2013: Fully Revised and Updated
M2 - Mon Nov 18, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/vdd85f/copromotion_and) has announced the addition of the "Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering. The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Revised and updated 9th edition, includes: - Trends in co-promotion and co-marketing deals - Co-promotion and co-marketing agreement structure - Co-promotion and co-marketing contract documents - Top co-promotion deals by value - Top co-marketing deals by value - Most active co-promotion dealmakers - Most active co-marketing dealmakers This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2007 to end of Sep 2013. This report contains over 850 links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners. Companies Mentioned: - Abbott Japan - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - Boehringer Ingelheim - Bristol-Myers Squibb - Cardiome Pharma - Celgene - Dyax - Dynavax Technologies - Eisai - Eli Lilly - Enanta Pharmaceuticals - Endo Pharmaceuticals - Exelixis - Facet Biotechnology - Forest Laboratories - Genentech - GlaxoSmithKline - Hyperion Therapeutics - Ironwood Pharmaceuticals - Janssen Research & Development - KaloBios Pharmaceuticals - La Jolla Pharmaceutical - Macrogenics - MAP Pharmaceuticals - Maxygen - Merck and Co - Novartis - Nycomed - OncoGenex Pharmaceuticals - Pfizer - Procter & Gamble Pharmaceuticals - Purdue Pharma - Regeneron Pharmaceuticals - Salix Pharmaceuticals - Schering-Plough - Solvay - TAP Pharmaceutical - Teva Pharmaceuticals - Tibotec - Transcept Pharmaceuticals - Ucyclyd Pharma - Valeant Pharmaceuticals - Watson Pharmaceuticals - Wyeth - Xenoport - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/vd...motion_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Constipation - Pipeline Review, H2 2013
M2 - Tue Oct 08, 3:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jrnmrc/constipation) has announced the addition of the "Constipation - Pipeline Review, H2 2013" report to their offering. 'Constipation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for constipation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for constipation. The analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Scope - A snapshot of the global therapeutic scenario for Constipation. - A review of the Constipation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Constipation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Constipation Overview Therapeutics Development An Overview of Pipeline Products for Constipation Constipation Therapeutics under Development by Companies Constipation Therapeutics under Investigation by Universities/Institutes Constipation - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles - RM-131 - naronapride - prucalopride succinate - linaclotide - lubiprostone - MDT-006 - velusetrag - YKP-10811 - elobixibat - Drug For Chronic Constipation - DA-6886 - BLI-801 - AZD-1722 - YH-12852 - DSP-6952 - KWA-0711 - mexiletine hydrochloride - ASP-7663 - 5-BOIP Constipation Therapeutics - Drug Profile Updates Constipation Therapeutics - Dormant Products Constipation - Product Development Milestones Featured News & Press Releases Appendix Methodology Coverage Secondary Research Primary Research Companies Mentioned - ARYx Therapeutics - Astellas Pharma Inc. - AstraZeneca PLC - Beech Tree Labs, Inc. - Braintree Laboratories, Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Dong-A Pharmaceutical Co., Ltd. - Ferring Pharmaceuticals, Inc. - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - MicroDose Therapeutx, Inc. - Rhythm Pharmaceuticals - Shire Plc - Sucampo Pharmaceuticals, Inc. - SunTen Phytotech Co., Ltd. - Synergy Pharmaceuticals, Inc. - Theravance, Inc. - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/jr...nstipation

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqxvxn/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Functional (Non Ulcer) Dyspepsia therapeutic pipeline. This report provides information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia. 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012' is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERA
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 70

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 116

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 174

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 105

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 9

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 128

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 73

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 160

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 40

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading

Top 5 Most Recently Viewed Articles

Critical Updates for iRobot Corporation Investors and Class Action

Updated Category News Views 128

Urgent Notice for iRobot Corporation Investors Attention to all investors of iRobot Corporation (NASDAQ: IRBT)! If you have purchased securities between January 29, 2024, and March 11, 2025, it is crucial to be aware of a significant deadline approaching on September 5, 2025. This notice aims to inform and guide you through this pressing matter. Why You Should Act Now The...

Continue Reading
NeuralTrust Expands to London as AI Risks Intensify

Updated Category News Views 26

NeuralTrust's Strategic London Expansion In a world where AI agents are sprinting ahead of our security instincts, NeuralTrust makes a big play in the UK market, locking in their position with a new London office. This move isn't just about expansion—it's about tackling the tide of challenges head-on that comes with putting AI agents into the wild. London: A Hub for...

Continue Reading
Virtu Financial Reports Strong Q3 2025 Performance Highlights

Updated Category News Views 227

Virtu Financial's Q3 2025 Financial Overview As of the end of the third quarter in 2025, Virtu Financial, Inc. (NYSE: VIRT), a prominent player in the financial services sector, reported impressive results showcasing their financial strength through market challenges. Performance Metrics at a Glance During the third quarter, Virtu experienced substantial growth with a net...

Continue Reading
Understanding Super Micro Computer's Options Activity Trends

Updated Category News Views 219

Understanding Super Micro Computer's Options Activity Trends Recent movements in the options market for Super Micro Computer (SMCI) have caught the attention of investors. The influx of significant bearish activities suggests a pivotal moment could be approaching for the company. Observing the options market can provide insights into potential stock behavior, something...

Continue Reading
HUAWEI AppGallery Promises Unforgettable Gaming at Gamescom

Updated Category News Views 318

Exciting Countdown to Gamescom 2025 One Week Countdown! Prepare for an exhilarating gaming adventure as HUAWEI AppGallery gears up for an unforgettable experience at Gamescom 2025! With just one week left, gamers are invited to immerse themselves in the excitement at Booth A.040. This event promises a fantastic blend of hands-on gameplay, vibrant community activations,...

Continue Reading